AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04830423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medical ozone injection
Description: Patients in the ozone (O2-O3) injection group will be given intraarticular and periarticular knee injections 3 times as the first dose of 10 μg / ml, the second dose is 15 μg / ml, and the third dose is 20 μg / ml, each session in a volume of 10 ml. Patients will be evaluated according to the study criteria at the beginning, 4 and 12 weeks later by a blinded investigator.
Study NCT04830423 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: steroid injection group
Description: In the steroid injection group, 1 ml of betamethasone (6 mg / ml) will be injected once intraarticular knee injection. Patients will be evaluated according to the study criteria at the beginning, 4 and 12 weeks later by a blinded investigator.
Study NCT05672654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Blood draw
Study NCT06552286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRW-T
Description: The STRW-T intervention consists of 15 weekly caregiver group sessions and caregiver-teen dyad sessions delivered via Zoom. The targeted daily living skills (DLS) have been identified and refined through our prior studies and include: Morning routine, laundry, kitchen/cooking, grocery shopping, and money management. Evidence-based strategies are utilized to facilitate acquisition, mastery, and generalization of specific DLS at home and in the community. During dyad sessions, teens will work on DLS in their home environment and will receive coaching and instruction from both their caregiver and the therapist. During caregiver group sessions, the therapist will discuss the content of dyad sessions and engage in problem solving with each caregiver (e.g., using and fading rewards, implementing strategies to increase success, teen motivation/buy-in).
Study NCT06552286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PEERS-T
Description: PEERS-T is a 15-week intervention with concurrent caregiver and teen group telehealth sessions that target social skills (e.g., building friendships, conversing, dealing with bullying). PEERS-T was chosen as the control because it is one of the few evidence-based interventions for autistic adolescents and does not address daily living skills. PEERS-T is also matched to STRW-T on duration and is clinically meaningful to families.
Study NCT06151418 — intervention group
Intervention type: DRUG
Intervention: Novel hormonal therapy
Description: As provided in real-world setting
Study NCT05671692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone
Description: Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial
Study NCT05671692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as active comparator, except placebo dispensed.
Study NCT03679247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention will be a clinical decision support (CDS) system that contains three main features: 1) methods to synthesize electronic health record (EHR) data in order to identify under-diagnosed chronic conditions (synthesize existing medical data to increase recognition of CKD and uncontrolled HTN in CKD patients and deliver management recommendations based on this evidence), 2) improve the design and content of the CDS using human factors methods, specifically usability testing, and 3) the use of two behavioral nudges (pre-checked default orders and an email to obtain commitment from PCPs to obtain their commitment to follow the CDS recommendations).
Study NCT03679247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Usual Care, PCP will receive an email with general information about CKD guidelines
Study NCT05442840 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral and drugs already approved and available for diabetes management
Description: Pharmacists will review the patients information and medical history as well as drug coverage to discuss preferred treatment options to manage diabetes based on recommendations from Diabetes Canada treatment guidelines; all drugs have been approved and are available on the market; pharmacists will offer frequent follow up and provide basic diabetes education to the patient at each follow up appointment
Study NCT05443191 — intervention group
Intervention type: DRUG
Intervention: Semaglutide
Description: Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
Study NCT06102954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Falls prevention intervention including exercise and educational components
Description: This includes five domains of exercise (strength, balance, flexibility, coordination, and endurance) and educational components to manage other falls risk factors (polypharmacy, nutrition, pain, orthostatic hypotension, poor vision and environmental hazard evaluations).
Study NCT05292794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CereGate Software; BSN cDBS Programmer; BSN Burst Programmer
Description: CereGate's objective is to, with a single DBS system implanted in the standard STN location for PD:~(i) deliver conventional tonic DBS stimulation of STN-to mitigate dopamine-responsive symptoms; and concurrently (ii) deliver bursting DBS-induced cueing stimulation-to mitigate FOG.~The sole function of CereGate Software is to guide the clinician through a systematic investigation of the stimulation parameter space to thereby configure / tune CereGate Therapy for each participant. CereGate Software proposes parameters for the clinician to evaluate and assists in documenting the response. It does not send commands to, nor control the output of, the DBS System.
Study NCT05971316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foam Roller
Description: General Warm-up + Foam Roller
Study NCT04938908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ophthalmic Probiotic
Description: Bacterial lysate of Lactobacillus sakei, hydroxypropylmethylcellulose (HPMC), boric acid, sodium chloride, purified water.
Study NCT04938908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opthalmic Placebo
Description: Placebo contains complete formulation of the active drug except for bacterial lysate of Lactobacillus sakei (i.e. HPMC, boric acid, sodium chloride, purified water)
Study NCT04938908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Opthalmic Placebo
Description: Placebo contains complete formulation of the active drug except for bacterial lysate of Lactobacillus sakei (i.e. HPMC, boric acid, sodium chloride, purified water)
Study NCT04938908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Probiotic Capsule
Description: Live Lactobacillus sakei (5 billion cfus) in hydroxypropylmethylcellulose hard capsule, with maltodextrin excipient
Study NCT04938908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Placebo Capsule
Description: Hydroxypropylmethylcellulose hard capsule, filled with maltodextrin excipient
Study NCT04938908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo Capsule
Description: Hydroxypropylmethylcellulose hard capsule, filled with maltodextrin excipient
Study NCT06252181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electromagnetic pulsed therapy
Description: patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise ( exercise will be applied 3 times per the week for eight week) and 3 sessions per weeks of 8-week electromagnetic one-hour pulsed therapy
Study NCT06252181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: elliptical exercise
Description: patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise (n=20 patients, exercise will be applied 3 times per the week for eight week)
Study NCT06410430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ba-Duan-Jin
Description: Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful ovements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear.
Study NCT05192200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Beta Interferon (PF-06823859)
Description: IV infusion
Study NCT04814303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: After applying standard monitoring of pulse oximetry, ECG, NIBP; while the patient in the sitting position following complete sterile aseptic condition after sterilization bovine bethidine spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral levels using a 25- gauge Whitacre needle. Intrathecal morphine 150 μg will be added to patients of both groups. Supplemental oxygen will be administered via a simple face mask.
Study NCT04814303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal block
Description: The block will be performed in the mid adductor canal to block both the saphenous and the nerve to vastus medialis. After skin infiltration with 1 to 2 mL of 2% lidocaine, an 80-mm, 22-gauge, short-bevel echogenic needle is advanced in plane with the ultrasound beam in an anterior-to-posterior direction until the tip is located within the adductor canal deep to the vastoadductor membrane. After negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection plane. The study solution will be injected within the canal adjacent to the femoral artery. Patients in group 1 received 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine and 4 mg dexamethasone.
Study NCT04814303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-articular Infilteration
Description: the surgeon will perform the PAI intra-operatively; 150 mL of 0.25% bupivacaine with 1:400,000 epinephrine, 30 mg of ketorolac, and 8 mg dexamethasone. Half of the solution will be administered into the posterior capsule and posterior soft tissues of the knee under direct vision after osteotomy but before insertion of the implants. The remaining half of the solution will be administered into the anterior soft tissues after placement of the implants and before skin closure. All local infiltration will be carried out while a thigh tourniquet (used to limit surgical bleeding) was inflated at a pressure of 300 to 350 mm Hg.
Study NCT04869631 — intervention group
Intervention type: OTHER
Intervention: The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.
Description: We aim to compare patients with aortic valve stenosis with and without cardiac amyloidosis.
Study NCT05225311 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Patients will be followed by the registry for life-long outcomes.
Study NCT05711576 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of a placebo mouthwash
Study NCT05711576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full mouth disinfection
Description: Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of full mouth disinfection (FMD) approach
Study NCT06092762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: subcutaneous injection every 2 weeks
Study NCT05830500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsule
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation simultaneously.
Study NCT03728907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing aid fitting technique- audiologist or user-adjusted
Description: See information under 'arm' description
Study NCT03728907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid fitting technique- audiologist or user-adjusted
Description: See information under 'arm' description
Study NCT05511181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioWave
Description: The BioWave device is called BioWaveGO. It is a FDA 510(k) cleared high frequency sinusoidal neurostimulator
Study NCT05511181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: The TENS device is called Intensity 5000. It is a FDA 510(k) cleared TENS device
Study NCT04986163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDSTORM monitor
Description: The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC and the second monitor used is MEDSTORM.
Study NCT04986163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor
Description: The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC-PRO and the second monitor used is MEDASENSE.
Study NCT04986163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive analgesia monitoring with MEDSTORM monitor and MEDASENSE monitor
Description: The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is MEDSTORM and the second monitor used is MEDASENSE.
Study NCT06172452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Body Neutrality SSI
Description: Online, 30-minute self-guided intervention for youth ages 13-17
Study NCT06172452 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Therapy SSI
Description: Online, 30-minute self-guided activity for youth ages 13-17
Study NCT05920798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05920798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05920798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05920798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05920798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Description: Given ID
Study NCT05920798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05920798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pheresis
Description: Undergo apheresis
Study NCT05416333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelaic acid
Description: Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months
Study NCT05416333 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: usual medication for CCCA
Description: Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months
Study NCT04737512 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based ADHD Treatment for Children
Description: MBAT-C is derived from Mindfulness-Based Stress Reduction (MBSR), a well-known and extensively-studied mindfulness intervention. Unlike all other mindfulness-based interventions, however, MBAT-C is tailored to the needs, abilities, and vulnerabilities of children with ADHD through the use of age-appropriate class length, homework assignments, contemplative practices, and discussion topics.
Study NCT04737512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based ADHD Treatment for Children
Description: MBAT-C is derived from Mindfulness-Based Stress Reduction (MBSR), a well-known and extensively-studied mindfulness intervention. Unlike all other mindfulness-based interventions, however, MBAT-C is tailored to the needs, abilities, and vulnerabilities of children with ADHD through the use of age-appropriate class length, homework assignments, contemplative practices, and discussion topics.
Study NCT04737512 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal-Standard Medication (Treatment as Usual)
Description: Participants will receive gold-standard, non-experimental medication. This treatment arm relies on a step-by-step approach that is designed to mimic pharmacologic treatment-as-usual in the community. The treatment algorithm is as follows:~1. All participants will start with Concerta; Ritalin may be started if the effect of Concerta wears off mid-day;~2. If Concerta +/- Ritalin is ineffective or not tolerated, participants will progress to Vyvanse; Adderall may be started if the effect of Vyvanse wears off mid-day;~3. If Vyvanse +/- Adderall is also ineffective or not tolerated, participants will progress to Kapvay;~4. If Kapvay is ineffective or not tolerated, participants will progress to Intuniv.~5. Alternative combinations of the above medications will be considered if the above combinations are ineffective or otherwise not tolerated.
Study NCT05557916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehab
Description: Standard rehab protocol including knee orthosis following meniscal repair
Study NCT05557916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: accelerated rehab group
Description: accelerated rehab group, no orthosis
Study NCT06473922 — intervention group
Intervention type: PROCEDURE
Intervention: Reginal anesthesia
Description: General anesthesia
Study NCT05035524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate Solution
Description: Inhalation of SB 8.4% via a jet nebulizer (5 ml every 4 h) starting at 7:00 to 23:00 hours every day for 30 days together with instillation of SB 8.4% drops 4-times daily (three drops for each nostril) were offered to all patients in the study group (El-Badrawy et al., 2019).
Study NCT05035524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05478408 — intervention group
Intervention type: OTHER
Intervention: Questionnaires set
Description: Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
Study NCT04839341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
Study NCT06510374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadofaragene Firadenovec
Description: Vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification.
Study NCT05476445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Root canal treatment
Study NCT06378268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone 10 mg
Description: Dydrogesterone 10mg orally 2 times daily, starting on the day of gonadotropin injection to the oocyte maturation trigger night.
Study NCT06378268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix 0.25 mg
Description: Cetrorelix 0.25mg is injected subcutaneously once a day. It is given from day 5 or day 6 of stimulation by the oocyte maturation trigger day.
Study NCT05476445 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Root canal treatment+Laser application
Study NCT05476445 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Root canal treatment + Cryotherapy application
Study NCT05769296 — intervention group
Intervention type: DEVICE
Intervention: Headpulse measurements
Description: Placement of headset on subject
Study NCT05330312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioral therapy
Description: Therapy for patients with pulmonary fibrosis
Study NCT04842747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERU-111
Description: Subjects in the VERU-111 treatment groups will receive standard of care, plus oral daily VERU-111 9mg for 21 days or until released from hospital.
Study NCT05362487 — intervention group
Intervention type: DEVICE
Intervention: Spiriva® Respimat®
Description: Spiriva® Respimat®
Study NCT05362487 — intervention group
Intervention type: DEVICE
Intervention: Spiriva® HandiHaler®
Description: Spiriva® HandiHaler®
Study NCT05362487 — intervention group
Intervention type: DRUG
Intervention: Tiotropium bromide
Description: Tiotropium bromide